ArticleChemical & biomedical imaging2026
Mitochondria-Targeting Accumulation of 5MEF Probe for Early Diagnosis of Myocardial Infarction.
Article in Chemical & biomedical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ultrasound-activated dual-targeted liposomes for visualized precise neuromodulation against myocardial ischemia-reperfusion injury.Materials today. Bio · 2026Article
- Glutathione responsive nanomedicine leverages tumor redox imbalance for targeted cancer theranostics.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction (MI) remains a leading cause of morbidity and mortality worldwide, necessitating the development of more precise diagnostic strategies beyond conventional biomarker detection and imaging techniques, which often suffer from limited specificity and sensitivity. Here, we report the design and evaluation of a mitochondria-targeting accumulation probe, 5MEF, for MI diagnosis. In vitro assays demonstrated that 5MEF exhibits high specificity and selective accumulation in H9c2 cells compared to that in HUVECs. In the rat MI model, 5MEF showed significant differences between the infarcted area and the noninfarcted area, indicating that 5MEF has diagnostic potential. Biosafety assessments conducted in vitro and in vivo revealed no significant cytotoxicity or adverse effects. In conclusion, our findings demonstrate that 5MEF is a highly promising molecular probe for the early detection of MI, providing a highly specific and safe diagnostic tool with a significant potential for clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.